Viavi price target raised to $70 from $42 at Rosenblatt

Rosenblatt analyst Mike Genovese raised the firm’s price target on Viavi (VIAV) to $70 from $42 and keeps a Buy rating on the shares following what the firm describes as “a clean 3Q26 beat-and-raise.” The firm is “even more bullish than management sounds because we expect the AI-driven expansion to last for multiple years,” the analyst tells investors.